Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • CARB-X Graduates
    • Spotlight on Science
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Jenner Institute

Jenner Institute, University of Oxford, Oxford, UK
https://www.jenner.ac.uk/

dmGC_0817560 NOMV
NATIVE OUTER MEMBRANE VESICLE (NOMV) VACCINE

Prevention of Gonorrhea

The Jenner Institute is developing a novel gonorrhea vaccine to prevent infections from different strains of gonococcal bacteria, including the most powerful multidrug-resistant strains that are spreading globally at an alarming pace. The vaccine consists of blebs, or fluid-filled blisters, from the outer surface of gonococcus, called Native Outer Membrane Vesicles (NOMV). Working alongside the Oxford Vaccine Group. The intent is that the vaccine will induce protective immunity against gonorrhea that will prevent individuals from developing the disease and also interrupt the spread of antibiotic resistance found in gonococcal bacteria. The CARB-X award is supporting optimization work and scale-up, followed by production of the vaccine in the University’s Clinical Biomanufacturing Facility for a first-in-human study. Jenner researchers aim to produce an affordable vaccine for global use. Gonorrhea is a disease affecting an estimated 78 million people world-wide, particularly women in low- and middle-income countries.

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of up to $2.0m with potential option payments up to $5.3m

Initial CARB-X Investment Date: January 1, 2021

Carb-X

Led by Boston University

Copyright 2022

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2022